ISTA Pharmaceuticals Stockholders Vote to Approve Acquisition by Bausch + Lomb
06 June 2012 - 4:25AM
Marketwired
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), announced that at the
special meeting of ISTA stockholders held today, ISTA's
stockholders voted to approve the adoption of the previously
announced Agreement and Plan of Merger, dated March 26, 2012, as
amended on May 24, 2012, by and among Bausch + Lomb Incorporated,
Inga Acquisition Corporation, a wholly-owned subsidiary of Bausch
& Lomb Incorporated, and ISTA.
The affirmative vote of the holders of a majority of the
outstanding shares of ISTA's common stock was required to approve
the proposal to adopt the merger agreement. According to the final
tally of shares voted, 78.5% of the outstanding shares of ISTA's
common stock as of the close of business on April 23, 2012, the
record date, were voted to approve the proposal to adopt the merger
agreement. A quorum of 79.32% of ISTA's total outstanding shares of
common stock as of the April 23, 2012 record date voted at the
special meeting.
The proposed merger was announced on March 26, 2012 and is
expected to close on June 6, 2012.
ABOUT ISTA PHARMACEUTICALS ISTA
Pharmaceuticals, Inc. is the third largest branded prescription eye
care business in the United States, with an expanding focus on
allergy therapeutics. ISTA currently markets four products,
including treatments for ocular inflammation and pain post-cataract
surgery, glaucoma, and ocular itching associated with allergic
conjunctivitis. The Company's development pipeline contains
additional candidates in various stages of development to treat dry
eye, ocular inflammation and pain, and nasal allergies.
Headquartered in Irvine, California, ISTA generated revenues of
$160 million in 2011. For additional information about ISTA, please
visit the corporate website at www.istavision.com.
ABOUT BAUSCH + LOMB Bausch + Lomb is one
of the best-known and most respected healthcare companies in the
world. Its core businesses include contact lenses and lens care
products, ophthalmic surgical devices and instruments, and
ophthalmic pharmaceuticals. Founded in 1853, the company is
headquartered in Rochester, N.Y., and employs roughly 11,000 people
worldwide. Its products are available in more than 100 countries.
More information is available at www.bausch.com.
FORWARD-LOOKING STATEMENTS Any statements
contained in this press release that refer to future events or
other non-historical matters are forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements are intended to qualify
for the safe harbor from liability established by the Private
Securities Reform Act of 1995. Without limiting the foregoing, but
by way of example, statements contained in this press release
related to the closing of the acquisition are forward-looking
statements. Except as required by law, ISTA disclaims any intent or
obligation to update any forward-looking statements. These
forward-looking statements are based on ISTA's expectations as of
the date of this press release and are subject to risks and
uncertainties that could cause actual results to differ materially.
Important factors that could cause actual results to differ from
current expectations are detailed from time to time in ISTA's
public filings with the U.S. Securities and Exchange Commission,
including but not limited to ISTA's Annual Report on Form 10-K for
the year ended December 31, 2011 and ISTA's Quarterly Report on
Form 10-Q for the quarter ended March 31, 2012.
For ISTA Investor Relations: Lauren Silvernail 949-788-5302
lsilvernail@istavision.com Jeanie Herbert 949-789-3159
jherbert@istavision.com For Bausch + Lomb Media Relations: Adam
Grossberg (973) 615-3416 adam.grossberg@bausch.com Teresa Panas
(973) 360-6382 Cell (862) 579 7186 Teresa.Panas@bausch.com
Ista Pharmaceuticals, Inc. (MM) (NASDAQ:ISTA)
Historical Stock Chart
From Apr 2024 to May 2024
Ista Pharmaceuticals, Inc. (MM) (NASDAQ:ISTA)
Historical Stock Chart
From May 2023 to May 2024